Ultragenyx Pharmaceutical
RARE
242 hedge funds and large institutions have $3.21B invested in Ultragenyx Pharmaceutical in 2023 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 89 increasing their positions, 82 reducing their positions, and 28 closing their positions.
46% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 28
16% more capital invested
Capital invested by funds: $2.76B → $3.21B (+$450M)
6% more funds holding
Funds holding: 229 → 242 (+13)
9% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 82
0.31% more ownership
Funds ownership: 97.86% → 98.17% (+0.31%)
1% less call options, than puts
Call options by funds: $14.7M | Put options by funds: $14.9M
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
+$124M |
| 2 |
RI
RTW Investments
New York
|
+$52.6M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$16.4M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$15.3M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$56.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$44.6M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$34.7M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$34.1M |
| 5 |
Millennium Management
New York
|
-$32.8M |
RARE Hedge Fund Activity: Q2 2023 in Review
242 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2023, worth a combined $3.21B — up 16% from $2.76B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new RARE positions and 28 closed out — a net gain of 13 holders — while 89 added to existing stakes and 82 trimmed.
The largest buyer was Sands Capital Management, opening a new position worth an estimated $124M. The largest seller was Avidity Partners Management, cutting an estimated $56.9M.
- 242 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2023, up from 229 in Q1 2023.
- Funds reported $3.21B of Ultragenyx Pharmaceutical stock for Q2 2023, up 16% quarter-over-quarter.
- 41 funds opened new Ultragenyx Pharmaceutical positions in Q2 2023 and 28 closed out, a net change of +13 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2023 was Sands Capital Management, an estimated $124M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2023 was Avidity Partners Management, an estimated $56.9M sold.
Based on aggregated 13F filings for Q2 2023.